A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
Launched by ARCE THERAPEUTICS, INC. · Mar 26, 2025
Trial Information
Current as of July 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the long-term safety of a treatment called ARD103 CAR-T cell therapy for patients who have certain types of blood cancers, specifically acute myeloid leukemia (AML) that has come back or hasn’t responded to other treatments, as well as myelodysplastic syndrome (MDS). If you or a loved one has previously received ARD103 CAR-T therapy and are interested in how it affects health over time, this study might be a good fit.
To participate, individuals must be 18 years or older, have had ARD103 therapy in a previous study, and be able to understand the study procedures. There are no specific exclusions, so many who meet the inclusion criteria may qualify. Participants in the trial can expect to be monitored for their health and safety over the long term, helping researchers understand how well the treatment works and any potential side effects that may arise over time. This study is not yet recruiting, but it represents an important step in learning more about CAR-T therapies for blood cancers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.
- • The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.
- Exclusion Criteria:
- • There are no specific exclusion criteria for this study
About Arce Therapeutics, Inc.
Arce Therapeutics, Inc. is a biopharmaceutical company dedicated to advancing innovative therapies for the treatment of rare and challenging diseases. Focused on leveraging cutting-edge research and development, Arce aims to address unmet medical needs through its robust pipeline of novel drug candidates. With a commitment to scientific excellence and patient-centric approaches, the company collaborates with leading researchers and healthcare professionals to bring transformative solutions to market. Arce Therapeutics is poised to make a meaningful impact in the field of medicine, enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported